Moderna Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 274m | 17.7b | 19.3b | 6.8b | 3.3b | 3.9b | 5.7b |
| % growth | 471 % | 6361 % | 9 % | (65 %) | (51 %) | 20 % | 45 % |
| EBITDA | (763m) | 13.3b | 9.8b | (3.2b) | (3.5b) | (2.7b) | (1.6b) |
| % EBITDA margin | (278 %) | 75 % | 51 % | (48 %) | (106 %) | (67 %) | (28 %) |
| Profit | (747m) | 12.2b | 8.4b | (4.7b) | (3.6b) | (2.8b) | (1.4b) |
| % profit margin | (272 %) | 69 % | 43 % | (70 %) | (108 %) | (70 %) | (24 %) |
| EV / revenue | 134.2x | 5.2x | 3.1x | 4.3x | 7.0x | 6.5x | 4.8x |
| EV / EBITDA | -48.3x | 7.0x | 6.0x | -9.1x | -6.6x | -9.6x | -17.2x |
| R&D budget | 1.4b | 2.0b | 3.3b | 4.8b | - | - | - |
| R&D % of revenue | 499 % | 11 % | 17 % | 72 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$40.0m | Late VC | ||
$24.6m | Grant | ||
| N/A | $110m | Late VC | |
$25.0m | Late VC | ||
$450m Valuation: $3.0b | Late VC | ||
$20.0m | Grant | ||
| N/A | $474m | Growth Equity VC | |
* | $500m Valuation: $7.5b 42.4x EV/LTM Revenues -31.9x EV/LTM EBITDA | Series G | |
$125m | Series H | ||
| N/A | $604m Valuation: $7.5b 42.4x EV/LTM Revenues -31.9x EV/LTM EBITDA | IPO | |
$430m | Grant | ||
$53.0m | Grant | ||
$472m | Grant | ||
$1.5b | Grant | ||
$1.7b | Grant | ||
* | $250m | Post IPO Equity | |
* | $750m | Post IPO Equity | |
* | $176m | Grant | |
| Total Funding | CAD8.3b | ||
Recent News about Moderna Therapeutics
EditAt Moderna, we believe messenger RNA, or mRNA, is the “software of life.”
Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.
Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.
We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
To learn more, visit www.modernatx.com.
This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).
Tech stack
Investments by Moderna Therapeutics
Edit
